Filament Health Corp (NEO:FH, OTCQB:FLHLF) announced that its botanical psilocybin drug candidate, PEX010, will be studied at the University of Wisconsin–Madison (UW–Madison) in two Food and Drug Administration-authorized clinical trials.
The trials will explore the effects of psilocybin on neuroplasticity, the brain’s ability to reorganize and form new neural connections, which may offer therapeutic benefits for mental health.
The first trial, called The ENHANCE Study, is being funded by the Tiny Blue Dot Foundation. It will focus on 100 healthy volunteers to investigate whether enhancing psychedelic-induced neuroplasticity can expand the "Perception Box," a concept introduced by the foundation's founder, Elizabeth Koch.
The Perception Box represents the internal beliefs and biases that shape an individual’s worldview, and the study aims to determine if expanding it through psychedelics can reduce suffering, foster self-acceptance, and increase empathy.
The second clinical trial, The RECAP2 Study, will examine the long-term effects of psilocybin on wellbeing, enrolling 60 healthy volunteers with mild declines in their mental health.
Both trials, expected to begin in the first quarter of 2025, are part of a broader initiative to investigate how neuroplasticity may support lasting improvements in participants' perceptions and overall wellbeing.
Dr Charles Raison, professor of psychiatry at the University of Wisconsin School of Medicine and Public Health in Madison, is serving as principal investigator of both trials.
"Our goal with this research is to examine how psilocybin's effects on neuroplasticity may impact participants' wellbeing and their ability to understand the world around them," Dr Raison said in a statement.
Benjamin Lightburn, Filament Health CEO, highlighted that UW-Madison is an internationally recognized leader in psychiatric research.
"We are proud that Dr Raison and his team have selected Filament's drug candidate for clinical trials of this calibre and we're pleased to support their important research," Lightburn said.
Filament’s PEX010 has already been authorized for investigation in 41 clinical trials globally across 14 mental health indications.